• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: IV PORT; CATHETER, INTRAVASCULAR, THERAPEUTIC, SHORT-TERM LESS THAN 30 DAYS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

IV PORT; CATHETER, INTRAVASCULAR, THERAPEUTIC, SHORT-TERM LESS THAN 30 DAYS Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Unspecified Infection (1930); Pain (1994)
Event Type  Injury  
Event Description
Patient stated she had a 5-day stay at the local hospital last week.Her oncologist isn't sure if it's due to the ziextenzo or the iv port she just had placed in which might have caused an infection at the port site.Pt went to hospital due to flu-like symptoms such as aches/pain.Pt was told her lactic acid levels were elevated.She stated her oncologist is fully aware of everything and she takes her next shot next week and the oncologist will monitor her.Unknown exact dates of hospitalization.No further information provided.Reported to (b)(6) by pt/caregiver.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
IV PORT
Type of Device
CATHETER, INTRAVASCULAR, THERAPEUTIC, SHORT-TERM LESS THAN 30 DAYS
MDR Report Key15259129
MDR Text Key298410481
Report NumberMW5111602
Device Sequence Number1
Product Code FOZ
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Voluntary
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 08/17/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received Not provided
Initial Date FDA Received08/18/2022
Patient Sequence Number1
Treatment
ZIEXTENZO PFS 6 MG/0.6 ML, MFR: SANDOZ
Patient Outcome(s) Hospitalization;
Patient SexFemale
-
-